Wells Fargo raised the firm’s price target on Glaukos (GKOS) to $122 from $120 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EPS beat and raised FY25 guidance by $9.5M. Management provided preliminary FY26 sales outlook bracketing consensus. Wells raised its Epioxa and iDose estimates.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Strong Buy Rating for Glaukos Driven by iDose Success and Positive Revenue Projections
- Glaukos’s Strong Growth Prospects: Buy Rating Affirmed Amid Surpassing Sales and Promising Pipeline
- Glaukos Corp. Reports Record Q3 Sales Growth
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
- Glaukos Reports Record Q3 2025 Sales Growth